Many breast and endometrial cancer survivors do not get enough physical activity. Technology-based interventions can be inexpensive and easy to scale up, however they are not effective for all women. The purpose of this study is test an adaptive physical activity intervention approach that reserves the most resources and support for women who do not fare well with a lower-cost, minimal intervention. The results from this trial will inform the development of scalable physical activity interventions for breast and endometrial cancer survivors.

开始日期2020-11-09

申办/合作机构

University of Wisconsin-Madison

[+2]

NCT04017845

/ Completed早期临床1期IIT

Screening for Colorectal Cancer in Average and High Risk Iraqi Population: A Pilot Study

The existing evidence from epidemiological studies and randomized controlled trials has consistently assures the cost effectiveness and the influential role of screening in reducing incidence rates and deaths caused by Colorectal Cancer (CRC). Population based organized screening programmes, which should be considered an obligation that is not to be postponed, require valuable information that can be reliably extrapolated from well-designed pilot study conducted prior to programme implementation.
The main objectives of the current pilot CRC screening project, named after "Al-Kindy College of Medicine", was to evaluate and explore the specific aspects of the intended population-based organized CRC screening programme, including: barriers affecting adherence to the programme, performance indicators of the proposed screening programme, the target population in which CRC screening is a legitimate healthcare priority, quality assurance of screening tests and colonoscopy services, and to propose an algorithm that will provide a clinically and logistically acceptable positivity rate.

开始日期2015-04-01

申办/合作机构

Al-Kindy College of Medicine

[+1]

100 项与利多卡因/三苄糖苷相关的临床结果

登录后查看更多信息

100 项与利多卡因/三苄糖苷相关的转化医学

登录后查看更多信息

100 项与利多卡因/三苄糖苷相关的专利（医药）

登录后查看更多信息

项与利多卡因/三苄糖苷相关的文献（医药）

2026-05-01·Biomaterials advances

Paotianxiong polysaccharides as a stabilizer for protein nanoparticles and construction of an enhanced gastric acid-responsive hydrogel for delivery of fisetin to alleviate alcoholic gastric injury

Article

作者: He, Chenghao ; Jiang, Jiaxin ; Ren, Qiao ; Liu, Jiayizhuo ; Hou, Shuguang ; Huang, Qinwan ; Jiang, Jingcheng

Long-term excessive alcohol intake can easily lead to gastritis, gastric ulcer, and gastric bleeding. To address fisetin's (FIT) limitations in ameliorating alcohol-induced gastric injury while resolving stability issues of pH-driven albumin nanoparticles and oral protein-based drug delivery carriers, this study innovatively employed Paotianxiong polysaccharides (PP) as a stabilizer for protein nanoparticles and constructed an enhanced gastric acid-responsive hydrogel for delivery of FIT to alleviate alcohol-induced gastric injury. Through a green strategy (pH-driven method), albumin-PP composite nanoparticles were fabricated to improve FIT's solubility, stability, and bioavailability. The nanoparticles exhibit a uniform particle size and excellent dispersibility. In different pH acidic environments and ionic concentrations, the addition of PP significantly boosts the nanoparticles' stability. To further enhance gastric retention and sustained drug-release properties, an acid-responsive hydrogel was designed using SA and Ca²⁺, and carboxymethyl chitosan and PP were introduced to optimize the hydrogel's toughness, bioadhesion, and biocompatibility. This gastric-retentive delivery system formed by incorporating drug-loaded composite nanoparticles into the hydrogel shows a denser network structure, excellent mechanical properties, bioadhesion, sustained-release and gastric-retentive properties. In vivo studies demonstrate that the drugs delivered by this system exhibit superior distribution characteristics in the stomach and liver. They can effectively alleviate alcohol-induced gastric injury by accelerating hepatic ethanol metabolism, regulating oxidative stress and inflammatory responses in gastric tissues, and inhibiting pyroptosis. Finally, this delivery system is composed of biomaterials, conferring excellent safety. This delivery system provides new strategies for improving the stability of protein nanoparticles and ameliorating alcohol-induced gastric injury, respectively.

2026-02-01·BRITISH JOURNAL OF GENERAL PRACTICE

Evaluating the role of faecal calprotectin in older adults: a retrospective observational study

Article

作者: Majeed, Azeem ; Martinez Perez, Pablo ; Foulser, Peter Fg ; Radhakrishnan, Shiva T ; Alexander, James L ; Williams, Horace Rt ; Sundramoorthi, Rohan ; Kumaran, Mithun ; Sharma, Angelica ; Zhang, David ; Mummery, David ; Taylor, Shakira ; Hicks, Lucy C ; Balarajah, Sharmili ; Perry, Robert W ; Chung, Carmen My

Background:

Faecal calprotectin (FC) is a marker of gastrointestinal (GI) inflammation that is widely used in primary care to identify patients who need to be referred for endoscopic assessment. Most guidelines advise against its use in older adults because of higher rates of colorectal cancer (CRC) in this group, and many studies include only younger adults, even though FC is still used in older adults.

Aim:

To evaluate FC performance in identifying inflammatory bowel disease (IBD) and significant organic pathology in adults aged ≥50 years, to help inform its use and interpretation in primary care. Where available, faecal immunochemical test (FIT) data were also analysed.

Design and setting:

A retrospective observational study of patients who were referred from primary care to secondary care for colonoscopy at Imperial College Healthcare NHS Trust.

Method:

Patients who had undergone FC testing, followed by a colonoscopy, were recruited and grouped into younger adults (aged 18–49 years) and older adults (aged ≥50 years). Data were then collected using electronic health records to allow for analysis of FC diagnostic performance.

Results:

In total, 669 patients were included: 423 aged 18–49 years and 246 aged ≥50 years. There were no significant differences in FC levels between the groups (median FC level: 71 µg/g versus 85.5 µg/g respectively, P = 0.29). An FC level of >50 µg/g showed a high sensitivity for inflammatory bowel disease (IBD) in both groups (94.1% in those aged 18–49 years and 93.8% in those aged ≥50 years), but the positive predictive value was low — particularly in those aged ≥50 years (12.8%) versus the younger cohort (20.9%). An FC level of >50 µg/g outperformed FIT (threshold 10 µg/g) for the diagnosis of IBD and organic pathology in both groups. However, in patients aged ≥50 years, FIT outperformed FC at 150 µg/g for the diagnosis of organic pathology, including CRC.

Conclusion:

These data show that FC remains a sensitive test in older adults. FC may have a role as a ‘rule-out’ test in adults aged ≥50 years who have lower GI symptoms and a negative FIT, when CRC is not suspected.

2025-07-01·BMJ Open Gastroenterology

Triaging colorectal urgent referrals in the COVID-19 era using faecal immunochemical testing: a prospective UK real-world multicentre cohort study

Article

作者: McDonald, Timothy ; Feeney, Mark ; Balasubramanya, Supriya ; Ward-Booth, Sally ; Walker, Gareth ; Bain, Iain ; Spencer, Naomi ; Bowen, Joel ; Kantola, Venla ; Bethune, Robert ; Smolarek, Sebastian ; Hamilton, Willie ; Bailey, Sarah E R ; Debab, Nedal ; Cartmell, Mark ; Renninson, John ; Faux, William ; Kennedy, Nicholas A

Objective:

During the early COVID-19 pandemic, UK guidelines advocated faecal immunochemical tests (FIT) with a threshold of 10 µg/g to help secondary care clinicians triage urgent suspected colorectal cancer (CRC) referrals. We aimed to evaluate the real-world performance and impact of FIT in a high-risk cohort referred against National Institute for Health and Clinical Excellence NG12 (2015) criteria.

Methods:

Multicentre prospective observational cohort study of FIT at all four secondary care hospitals in Devon (UK) between 1 April 2020 and 31 December 2020. FIT use was at the discretion of primary and secondary care clinicians. Incident CRC cases were identified ≥12 months after general practitioner (GP) referral using regional National Bowel Cancer Audit data linkage. We assessed diagnostic accuracy and healthcare utilisation in patients with and without FIT.

Results:

Overall, 6698 patients were included: 55% female, median age 72 years (IQR 65–82). Just over half (53%, 3552) of patients underwent FIT with a positivity rate of 34% (n=1237). CRC prevalence in patients with no FIT, positive FIT and negative FIT was 6% (189), 11% (137) and 0.5% (11), respectively. The prevalence of all cancers, including non-CRCs, was similar among FIT and no-FIT cohorts (p=0.74). Sensitivity and specificity of FIT for CRC were 0.93 (95% CI 0.87 to 0.96) and 0.68 (95% CI 0.66 to 0.69), respectively. Patients with negative FIT underwent fewer lower gastrointestinal endoscopies (no FIT 62% (1964) vs positive FIT 69% (857) vs negative FIT 36% (835)), p=0.0005).

Conclusions:

FIT is a useful triage tool for patients with suspected CRC which safely reduces endoscopy demand and prioritises those at greatest cancer risk. Standardised regional referral pathways, greater use of ‘straight-to-test’ investigations and GP support are needed to maximise its impact.

100 项与利多卡因/三苄糖苷相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肛裂	日本	Takeda Pharmaceutical Co., Ltd.	1994-04-01
肛裂	日本	Amato Pharmaceutical Products Ltd.	1994-04-01
痔疮	日本	Takeda Pharmaceutical Co., Ltd.	1982-12-15
痔疮	日本	Amato Pharmaceutical Products Ltd.	1982-12-15